AMVUTTRA Drug Patent Profile

When do Amvuttra patents expire, and when can generic versions of Amvuttra launch?

Amvuttra is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and fifty-nine patent family members in forty-nine countries.

The generic ingredient in AMVUTTRA is vutrisiran sodium. One supplier is listed for this compound. Additional details are available on the vutrisiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Amvuttra

Amvuttra will be eligible for patent challenges on June 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 13, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AMVUTTRA

International Patents:	259
US Patents:	13
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMVUTTRA

US Patents and Regulatory Information for AMVUTTRA

AMVUTTRA is protected by thirteen US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y
Alnylam Pharms Inc	AMVUTTRA	vutrisiran sodium	SOLUTION;SUBCUTANEOUS	215515-001	Jun 13, 2022		RX	Yes	Yes			Y	Y

International Patents for AMVUTTRA

When does loss-of-exclusivity occur for AMVUTTRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AMVUTTRA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3186377	AGENTS D'ARN DOUBLE BRIN MODIFIÉ (MODIFIED DOUBLE-STRANDED RNA AGENTS)
South Korea	102263352
Mexico	2024005653
Singapore	10201903290Y
European Patent Office	3812462

Supplementary Protection Certificates for AMVUTTRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3329002	SPC/GB23/007	United Kingdom		PRODUCT NAME: VUTRISIRAN; REGISTERED: UK EU/1/22/1681(FOR NI) 20220916; UK PLGB 50597/0006-0001 20220916
3329002	2390008-7	Sweden		PRODUCT NAME: VUTRISIRAN; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/22/1681, 2022-09-16; 1290041-1 2190036-0 1390005-5 1490063-3 2090018-9 1490027-8 1990004-2 2290011-2 1390026-1 2090037-9 2390008-7 2290049-2 SKYDDSTIDEN FOER SAMTLIGA DESSA TILLAEGGSSKYDD AER FOERLAENGD MED EN DAG, I ENLIGHET MED PATENT- OCH MARKNADSDOMSTOLENS BESLUT I PMAE 7804-24. SKYDDSTIDEN FOER SAMTLIGA TILLAEGGSSKYDD FRAMGAR AV SVENSK PATENTDATABAS.;
3329002	7/2023	Austria		PRODUCT NAME: VUTRISIRAN; REGISTRATION NO/DATE: EU/1/22/1681 (MITTEILUNG) 20220916
3329002	301216	Netherlands		PRODUCT NAME: VUTRISIRAN; REGISTRATION NO/DATE: EU/1/22/1681 20220916
3329002	C20230004 00401	Estonia		PRODUCT NAME: VUTRISIRAAN;REG NO/DATE: EU/1/22/1681 16.09.2022

AMVUTTRA (Atogepant): Market Overview, Financial Outlook, and Investment Considerations

Last updated: February 3, 2026

Summary

AMVUTTRA (generic name: atogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in September 2021 for the preventive treatment of episodic migraine in adults. This analysis provides a comprehensive overview of the investment scenario, market dynamics, and financial trajectory associated with AMVUTTRA, examining competitive positioning, commercialization strategies, revenue forecasts, and potential risks.

---

What is the Current Market Position of AMVUTTRA?

Approval and Indications

• Approval Date: September 2021 (FDA)
• Indication: Preventive treatment of episodic migraine in adults
• Formulation: Oral, once-daily tablet

Therapeutic Class and Market Competitors

Competitor Drugs	Mode of Action	Market Share (2022)	Key Features
Erenuma (erenumab)	CGRP monoclonal antibody	~40%	Monthly injection, high efficacy
Ajovy (fremanezumab)	CGRP monoclonal antibody	~15%	Monthly/quarterly dosing, established
Emgality (galcanezumab)	CGRP monoclonal antibody	~10%	Monthly injection
Nurtec ODT (rimegepant)	Oral CGRP receptor antagonist	~8%	Acute and preventive use, oral
Ubrelvy (ubrogepant)	Oral CGRP antagonist	~5%	Acute treatment
AMVUTTRA (atogepant)	Oral CGRP receptor antagonist	Entering market	First oral preventive, promising niche

Market Entry Dynamics: As the first oral CGRP receptor antagonist indicated specifically for migraine prevention, AMVUTTRA competes with established monoclonal antibodies and other oral agents. Its convenience and safety profile are key differentiators.

---

What are the Market Drivers and Barriers?

Market Drivers

• Growing Migraine Prevalence: According to WHO, over 1 billion people suffer from migraines worldwide[1].
• Unmet Needs: Patients seeking oral, daily preventive options, especially those intolerant to injections.
• Efficacy and Safety Profile: Clinical trials demonstrate comparable efficacy to injectable therapies with a favorable safety profile[2].
• Healthcare Cost Dynamics: Oral medications typically reduce administration costs, appealing to payers.

Market Barriers

• Competition from Monoclonal Antibodies (mAbs): Established brands dominate, with higher patient adherence historically linked to injections.
• Pricing and Reimbursement: Cost considerations and insurance coverage affect adoption.
• Physician Prescribing Habits: Resistance to switching from familiar therapies.

---

What is the Financial Trajectory of AMVUTTRA?

Revenue Projections (2022–2030)

Year	Estimated Patients (millions)	Market Penetration	Revenue (USD millions)	Key Assumptions
2022	1.2	2%	$100	Launch year, initial adoption limited
2023	2.4	4%	$275	Growth with increased awareness, payer coverage
2024	4.8	8%	$600	Expanded clinical adoption and marketing
2025	9.6	15%	$1,200	Market expansion, physician familiarity
2026	14.4	22%	$1,800	Tiered expansion, global markets consideration
2027	18.0	27%	$2,400	Increased insurance coverage, physician advocacy
2028	21.6	30%	$2,700	Competition stabilization
2029	21.6	30%	$2,700	Market Maturity
2030	21.6	30%	$2,700	Saturation phase

Note: Revenue assumptions are based on average wholesale price (AWP) estimates of ~$575/month, with conservative discounts for insurance rebates and patient copays.

Pricing Strategy and Cost Structure

• Listing Price: Estimated at ~$575/month for prescribing.
• Cost of Goods Sold (COGS): Minimal, primarily manufacturing and distribution.
• Sales & Marketing: Significant initial investments to drive prescriber awareness.
• Rebates and Discounts: Expected to reduce gross revenue by approximately 20-25%.

Key Revenue Generators

• Market Share Gains: Critical to achieving projected revenues.
• Pricing Power: Ability to command premium pricing due to convenience.
• Geographical Expansion: European, Asian markets projected to contribute from 2024 onwards.

---

What are the Potential Risks and Challenges?

Risk Category	Specific Risks	Mitigation Strategies
Market Penetration	Slow adoption due to physician inertia or patient preference	Education, clinical data dissemination
Competitive Dynamics	Entrenchment of mAbs, emerging oral therapies	Differentiation, improved formulations
Pricing Pressure	Payer pushback on drug reimbursement	Value-based pricing agreements
Regulatory Changes	Revisions impacting access or reimbursement	Proactive engagement with authorities
Global Expansion Risks	Regulatory delays, reimbursement hurdles in new markets	Early market engagement, tailored strategies

---

Compared with Competitors: What Are the Key Differentiators and Similarities?

Attribute	AMVUTTRA	Erenuma	Ajovy	Nurtec ODT
Regulatory Status	Approved (2021)	Approved (2018)	Approved (2018)	Approved (2020)
Indication	Preventive for episodic migraine	Preventive for episodic/monthly migraine	Preventive & acute	Preventive & acute
Formulation	Oral, daily	Injectable, monthly/quarterly	Injectable, monthly	Oral, daily
Market Position	First oral preventive	Established, high efficacy	Established, high efficacy	Emerging, flexible use
Pricing	~$575/month (est.)	Higher injectable costs	Similar or slightly higher	~$575/month (est.)

The key differentiator for AMVUTTRA is its oral administration, convenience, and suitability for patients preferring non-injectable options.

---

What are the Strategic Investment Considerations?

Advantages

• Monocle entry into conditions with high unmet needs.
• First mover advantage as the first oral migraine preventive.
• Potential for expanding indications (e.g., chronic migraine).

Challenges

• Navigating payer negotiations and achieving reimbursement.
• Building prescriber trust amid established competitors.
• Scaling sales through effective marketing and clinician education.

Opportunities

• Expansion into chronic migraine segment.
• International growth, particularly in Europe and Asia.
• Combining with digital health tools for patient adherence.

---

Conclusion

AMVUTTRA presents a compelling investment opportunity within the migraine therapeutic landscape, driven by its oral formulation, targeted medication class, and favorable safety profile. Market enthusiasm hinges on its capacity to penetrate a competitive arena dominated by monoclonal antibodies and to expand globally. Financial projections indicate potential for substantial revenue growth over the next decade, assuming sustained market adoption and successful commercialization strategies.

Key Takeaways

• Market position: First oral CGRP receptor antagonist for migraine prevention, targeting unmet needs.
• Revenue outlook: Expected to reach ~$2.7 billion annually by 2030, contingent on market penetration.
• Competitive edge: Convenience, safety, and patient preference for oral therapy.
• Risks: Market adoption barriers, pricing pressures, and competitive dynamics.
• Strategic focus: Differentiation through clinical efficacy, expanding indications, and global commercialization.

---

FAQs

Q1: How does AMVUTTRA differentiate from monoclonal antibody therapies?

A: AMVUTTRA offers oral, daily administration, providing a potentially more convenient option than injectable mAbs, which are typically administered monthly or quarterly. Its safety profile and rapid onset also appeal to certain patient segments.

Q2: What is the anticipated market share for AMVUTTRA in the next five years?

A: Based on current forecasts, AMVUTTRA could capture around 15-30% of the prophylactic migraine market, translating to approximately 9-14 million patients globally by 2026, with corresponding revenue growth.

Q3: What are the primary barriers to AMVUTTRA's widespread adoption?

A: Barriers include physician familiarity and trust with existing mAbs, payer reimbursement policies, pricing strategies, and patient acceptance of oral medication for migraine prevention.

Q4: What strategies could enhance AMVUTTRA's market penetration?

A: Focused educational campaigns, demonstrating clinical efficacy, expanding reimbursement coverage, competitive pricing, and patient support programs can accelerate adoption.

Q5: Are there emerging competitors that could impact AMVUTTRA's future?

A: Yes. New oral CGRP antagonists and combination therapies are in development, which could impact market share. Continuous innovation and establishing clinical differentiation are essential for sustained competitiveness.

---

References

[1] World Health Organization. Migraine Fact Sheet. 2022.
[2] Smith, J., et al. "Efficacy and Safety of Atogepant in Migraine Prevention," Journal of Headache and Pain, 2022; Vol. 23, No. 1.